REGENXBIO Inc. (RGNX)

NMS – Цена в реальном времени. Валюта: USD

10.24

+0.16 (1.59%)

При закрытии: May 12, 2026, 4:00 PM EDT

10.25

+0.01 (0.10%)

До открытия: May 13, 2026, 7:57 AM EDT

Обзор
Новости
График
Финансы
Дивиденды
Прогноз
Владельцы
Профиль

REGENXBIO Inc. (RGNX)

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

Контакты

Мы в соцсетях

REGENXBIO Inc. (RGNX)

REGENXBIO Announces Presentations at the American Society of Gene & Cell Therapy 2026 Annual Meeting

REGENXBIO to Host Webcast on May 14 to Discuss Topline Results from Pivotal Trial of RGX-202 for Duchenne Muscular Dystrophy

REGENXBIO Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - RGNX

RGNX Deadline Today: RGRX Investors Have Opportunity to Lead REGENXBIO, Inc. Securities Fraud Lawsuit

Bronstein, Gewirtz & Grossman LLC Urges REGENXBIO Inc. Investors to Act: Class Action Filed Alleging Investor Harm

RGNX Deadline Today: Rosen Law Firm Urges REGENXBIO, Inc. (NASDAQ: RGNX) Stockholders with Large Losses to Contact the Firm for Information About Their Rights

CLASS ACTION DEADLINE TONIGHT: Faruqi & Faruqi, LLP Reminds REGENXBIO (RGNX) Investors of the Securities Class Action Lawsuit Deadline on April 14, 2026

Видео

No Data

Пресс-релизы

REGENXBIO Announces Presentations at the American Society of Gene & Cell Therapy 2026 Annual Meeting

REGENXBIO Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - RGNX

RGNX Deadline Today: RGRX Investors Have Opportunity to Lead REGENXBIO, Inc. Securities Fraud Lawsuit

Bronstein, Gewirtz & Grossman LLC Urges REGENXBIO Inc. Investors to Act: Class Action Filed Alleging Investor Harm

Search stocks

REGENXBIO Inc. (RGNX)

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

Контакты

Мы в соцсетях

REGENXBIO Inc. (RGNX)

REGENXBIO Announces Presentations at the American Society of Gene & Cell Therapy 2026 Annual Meeting

REGENXBIO to Host Webcast on May 14 to Discuss Topline Results from Pivotal Trial of RGX-202 for Duchenne Muscular Dystrophy

REGENXBIO Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - RGNX

RGNX Deadline Today: RGRX Investors Have Opportunity to Lead REGENXBIO, Inc. Securities Fraud Lawsuit

Bronstein, Gewirtz & Grossman LLC Urges REGENXBIO Inc. Investors to Act: Class Action Filed Alleging Investor Harm

RGNX Deadline Today: Rosen Law Firm Urges REGENXBIO, Inc. (NASDAQ: RGNX) Stockholders with Large Losses to Contact the Firm for Information About Their Rights

CLASS ACTION DEADLINE TONIGHT: Faruqi & Faruqi, LLP Reminds REGENXBIO (RGNX) Investors of the Securities Class Action Lawsuit Deadline on April 14, 2026

Видео

No Data

Пресс-релизы

REGENXBIO Announces Presentations at the American Society of Gene & Cell Therapy 2026 Annual Meeting

REGENXBIO Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - RGNX

RGNX Deadline Today: RGRX Investors Have Opportunity to Lead REGENXBIO, Inc. Securities Fraud Lawsuit

Bronstein, Gewirtz & Grossman LLC Urges REGENXBIO Inc. Investors to Act: Class Action Filed Alleging Investor Harm